Looking at what has been paid for other companies with products that were pretty limited in amount of patients they could target (K maybe 20MM?), the recent poor test results of competing Prurisol products (Amgen at $4B/yr?), etc. I would say my statement is justified. The real killer value-added factor IMO is the totally unknown value of both K and P as compound facilitators (looking at pre-clinical success of K/Pfizer renal cancer drug and the just announced possibility for the K/Dr D drug as just 2 examples) and if each could result in 50 (?) new compounds (one connected medical person in an article said K alone could result in possibly thousands of compounds) and assume each compound brings in $300-400MM then what could the value be?
This will get me laughed at by quite a few but I think even $300/share could be a ridiculously low figure down the line should the pipeline prove commercial.
Am I expecting it, not really as I think they sell much earlier, but do I think one day we may look back and realize it could have been worth $300-$500 per share or more. That is why I believe a buyout for $150 or so is an absolute STEAL for big pharma. They can pay it to me now and I may bitch but I will take my millions and head off to my future fantasy life. LOL.
